94684
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 7
- fusion
- other ZFTA
- e1_e2
- E2
- umap1_2d
- -5.214862502
- umap2_2d
- 2.028613517
- umap1_3d
- 0.52679089
- umap2_3d
- -0.992874901
- umap3_3d
- -0.552512818
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- KRAS_SIGNALING_DN+0.300
- E2F_TARGETS+0.250
- G2M_CHECKPOINT+0.240
- ESTROGEN_RESPONSE_LATE+0.220
- APICAL_SURFACE+0.210
- SPERMATOGENESIS+0.210
- HYPOXIA+0.190
- GLYCOLYSIS+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- HEDGEHOG_SIGNALING-0.380
- DNA_REPAIR-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- NOTCH_SIGNALING-0.310
- OXIDATIVE_PHOSPHORYLATION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- ADIPOGENESIS-0.260
- HEME_METABOLISM-0.230
- MYC_TARGETS_V2-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG370 | — | — | 0.705 |
| 2 | R403 | — | — | 0.689 |
| 3 | EPT0808 | EPN | Posterior Fossa EPN | 0.675 |
| 4 | SRR8943025 | — | — | 0.670 |
| 5 | SRR1516036 | — | — | 0.664 |
| 6 | MNG934 | — | — | 0.663 |
| 7 | ee3e7969-ff2a-4b27-8f15-6cb46eed7c61 | — | — | 0.660 |
| 8 | MDT-AP-0317 | Med | Medulloblastoma | 0.658 |
| 9 | MNG24 | — | — | 0.652 |
| 10 | MNG157 | — | — | 0.645 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |